

Stephen R D Johnston

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6736744/stephen-r-d-johnston-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

64
papers

4,651
citations

27
h-index

68
g-index

68
ext. papers

5,739
ext. citations

7.2
avg, IF

5.54
L-index

| # | Paper | IF | Citations |
|----|--|------|-----------|
| 64 | Abstract PD15-03: Overlapping molecular features (proliferation, immune signatures and TP53 mutations) associated with palbociclib resistance in ER+HER2- primary breast cancer. <i>Cancer Research</i> , 2022 , 82, PD15-03-PD15-03 | 10.1 | |
| 63 | A review on the added value of whole-body MRI in metastatic lobular breast cancer.. <i>European Radiology</i> , 2022 , 1 | 8 | 0 |
| 62 | Reply to S. Sorscher. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1188-1189 | 2.2 | |
| 61 | Reply to K. Hashimoto and A. Shimomura. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1507-1508 | 2.2 | |
| 60 | Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: Updated Results. <i>Journal of Clinical Oncology</i> , 2021 , 39, 78-88 | 2.2 | 22 |
| 59 | Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3959-3977 | 2.2 | 16 |
| 58 | Health-Related Quality of Life in MONARCH 3: Abemaciclib plus an Aromatase Inhibitor as Initial Therapy in HR+, HER2- Advanced Breast Cancer. <i>Oncologist</i> , 2020 , 25, e1346-e1354 | 5.7 | 13 |
| 57 | Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor-Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFACT Trials. <i>Clinical Cancer Research</i> , 2020 , 26, 5172-5177 | 12.9 | 27 |
| 56 | Safety and efficacy of T-DM1 in patients with advanced HER2-positive breast cancer The Royal Marsden experience. <i>Cancer Treatment and Research Communications</i> , 2020 , 24, 100188 | 2 | 6 |
| 55 | Inactivating Mutations Are Enriched in Advanced Breast Cancer and Contribute to Endocrine Therapy Resistance. <i>Clinical Cancer Research</i> , 2020 , 26, 608-622 | 12.9 | 31 |
| 54 | A Prognostic Model Based on PAM50 and Clinical Variables (PAM50MET) for Metastatic Hormone Receptor-positive HER2-negative Breast Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 6141-6148 | 12.9 | 2 |
| 53 | Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE). <i>Journal of Clinical Oncology</i> , 2020 , 38, 3987-3998 | 23.2 | 152 |
| 52 | Pathological complete response to neoadjuvant systemic therapy in 789 early and locally advanced breast cancer patients: The Royal Marsden experience. <i>Breast Cancer Research and Treatment</i> , 2020 , 179, 101-111 | 4.4 | 13 |
| 51 | The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial. <i>JAMA Oncology</i> , 2020 , 6, 116-124 | 13.4 | 289 |
| 50 | MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. <i>Npj Breast Cancer</i> , 2019 , 5, 5 | 7.8 | 176 |
| 49 | Palbociclib and endocrine therapy in heavily pretreated hormone receptor-positive HER2-negative advanced breast cancer: the UK Compassionate Access Programme experience. <i>Breast Cancer Research and Treatment</i> , 2019 , 174, 731-740 | 4.4 | 12 |
| 48 | Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial. <i>Journal of Clinical Oncology</i> , 2019 , 37, 178-189 | 2.2 | 80 |

| | | | |
|----|--|------|-----|
| 47 | Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer. <i>JAMA Oncology</i> , 2019 , 5, 1473-1478 | 15.7 | 104 |
| 46 | Advances in Endocrine-Based Therapies for Estrogen Receptor-Positive Metastatic Breast Cancer. <i>Drugs</i> , 2019 , 79, 1849-1866 | 12.1 | 18 |
| 45 | Palbociclib plus endocrine therapy in older women with HR+/HER2- advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies. <i>European Journal of Cancer</i> , 2018 , 101, 123-133 | 7.5 | 34 |
| 44 | Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology, The</i> , 2018 , 19, 87-100 | 21.7 | 228 |
| 43 | Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: ALTERNATIVE. <i>Journal of Clinical Oncology</i> , 2018 , 36, 741-748 | 2.2 | 66 |
| 42 | Somatic cancer genetics in the UK: real-world data from phase I of the Cancer Research UK Stratified Medicine Programme. <i>ESMO Open</i> , 2018 , 3, e000408 | 6 | 2 |
| 41 | Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib. <i>JAMA Oncology</i> , 2016 , 2, 1287-1294 | 13.4 | 65 |
| 40 | Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2961-8 | 2.2 | 420 |
| 39 | Serum Human Epidermal Growth Factor 2 Extracellular Domain as a Predictive Biomarker for Lapatinib Treatment Efficacy in Patients With Advanced Breast Cancer. <i>Journal of Clinical Oncology</i> , 2016 , 34, 936-44 | 2.2 | 14 |
| 38 | Endocrine treatment for ductal carcinoma in situ: balancing risks and benefits. <i>Lancet, The</i> , 2016 , 387, 819-21 | 40 | 4 |
| 37 | Novel Treatments in Breast Cancer. <i>Clinical Medicine Insights Therapeutics</i> , 2016 , 8, CMT.S18492 | 0 | 0 |
| 36 | Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3069-103 | 2.2 | 341 |
| 35 | High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial. <i>Cancer Discovery</i> , 2016 , 6, 838-851 | 24.4 | 176 |
| 34 | Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Oncology, The</i> , 2016 , 17, 811-821 | 21.7 | 194 |
| 33 | Inhibition of EGFR, HER2, and HER3 signaling with AZD8931 in combination with anastrozole as an anticancer approach: Phase II randomized study in women with endocrine-therapy-naïve advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016 , 160, 91-99 | 4.4 | 22 |
| 32 | AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo. <i>Molecular Cancer Therapeutics</i> , 2015 , 14, 2035-48 | 6.1 | 43 |
| 31 | Enhancing Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: Cotargeting Signaling Pathways. <i>Journal of the National Cancer Institute</i> , 2015 , 107, | 9.7 | 65 |
| 30 | Dose-reduced trastuzumab emtansine: active and safe in acute hepatic dysfunction. <i>Case Reports in Oncology</i> , 2015 , 8, 113-21 | 1 | 4 |

| | | | |
|----|--|------|-----|
| 29 | The optimal duration of adjuvant endocrine therapy for early stage breast cancer--with what drugs and for how long?. <i>Current Oncology Reports</i> , 2014 , 16, 358 | 6.3 | 8 |
| 28 | New Approaches for Hormone-Receptor Positive Metastatic Breast Cancer. <i>Current Breast Cancer Reports</i> , 2013 , 5, 309-320 | 0.8 | |
| 27 | Treatment algorithms for hormone receptor-positive advanced breast cancer: going forward in endocrine therapy—overcoming resistance and introducing new agents. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013 , | 7.1 | 5 |
| 26 | Phase II randomized study of the EGFR, HER2, HER3 signaling inhibitor AZD8931 in combination with anastrozole (A) in women with endocrine therapy (ET) naive advanced breast cancer (MINT).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 531-531 | 2.2 | 12 |
| 25 | Progression-free survival (PFS) as surrogate endpoint for overall survival (OS) in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer (MBC): An individual patient data (IPD) analysis.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 610-610 | 2.2 | 1 |
| 24 | Integration of Ki67 with residual cancer burden (RCB) compared to Ki67 or RCB alone to predict long-term term outcome following neoadjuvant chemotherapy.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 535-535 | 2.2 | |
| 23 | A randomized phase II study (VEG108838) of lapatanib plus pazopanib (L+P) versus lapatanib (L) in patients with ErbB2+ inflammatory breast cancer (IBC).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 531-531 | 2.2 | 1 |
| 22 | ALTERNATIVE (EGF114299): A study of lapatinib, trastuzumab, and endocrine therapy in patients who received neo-/adjuvant trastuzumab (IV) and endocrine therapy.. <i>Journal of Clinical Oncology</i> , 2012 , 30, TPS661-TPS661 | 2.2 | |
| 21 | Chairperson's introduction: Despite significant advances in the diagnosis and treatment of breast cancer, approximately one third of patients still develop, and subsequently die from metastatic breast disease. <i>European Journal of Cancer</i> , 2011 , 47 Suppl 3, S4-5 | 7.5 | |
| 20 | The role of chemotherapy and targeted agents in patients with metastatic breast cancer. <i>European Journal of Cancer</i> , 2011 , 47 Suppl 3, S38-47 | 7.5 | 28 |
| 19 | Are we missing the mTOR target in breast cancer?. <i>Breast Cancer Research and Treatment</i> , 2011 , 128, 607-11 | 4.4 | 5 |
| 18 | New strategies in estrogen receptor-positive breast cancer. <i>Clinical Cancer Research</i> , 2010 , 16, 1979-87 | 12.9 | 152 |
| 17 | Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. <i>Journal of Clinical Oncology</i> , 2009 , 27, 5538-46 | 2.2 | 827 |
| 16 | Enhancing the efficacy of hormonal agents with selected targeted agents. <i>Clinical Breast Cancer</i> , 2009 , 9 Suppl 1, S28-36 | 3 | 45 |
| 15 | Are current drug development programmes realising the full potential of new agents? Introduction to Sessions 7 and 8. <i>Breast Cancer Research</i> , 2009 , 11 Suppl 3, S20 | 8.3 | |
| 14 | Are current drug development programmes realising the full potential of new agents? The scenario. <i>Breast Cancer Research</i> , 2009 , 11 Suppl 3, S21 | 8.3 | 3 |
| 13 | Hormone resistance. <i>Cancer Treatment and Research</i> , 2009 , 147, 1-33 | 3.5 | 2 |
| 12 | Integration of endocrine therapy with targeted agents. <i>Breast Cancer Research</i> , 2008 , 10 Suppl 4, S20 | 8.3 | 6 |

| | | | |
|----|--|------|-----|
| 11 | Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy. <i>Journal of Clinical Oncology</i> , 2008 , 26, 1066-72 | 2.2 | 164 |
| 10 | A phase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy. <i>Breast Cancer Research and Treatment</i> , 2008 , 110, 327-35 | 4.4 | 53 |
| 9 | Enhancing endocrine response with novel targeted therapies: why have the clinical trials to date failed to deliver on the preclinical promise?. <i>Cancer</i> , 2008 , 112, 710-717 | 6.4 | 15 |
| 8 | Clinical strategies for rationale combinations of aromatase inhibitors with novel therapies for breast cancer. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2007 , 106, 180-6 | 5.1 | 44 |
| 7 | Clinical efforts to combine endocrine agents with targeted therapies against epidermal growth factor receptor/human epidermal growth factor receptor 2 and mammalian target of rapamycin in breast cancer. <i>Clinical Cancer Research</i> , 2006 , 12, 1061s-1068s | 12.9 | 82 |
| 6 | Lapatinib: a novel EGFR/HER2 tyrosine kinase inhibitor for cancer. <i>Drugs of Today</i> , 2006 , 42, 441-53 | 2.5 | 105 |
| 5 | Endocrinology and hormone therapy in breast cancer: selective oestrogen receptor modulators and downregulators for breast cancer - have they lost their way?. <i>Breast Cancer Research</i> , 2005 , 7, 119-30 | 8.3 | 25 |
| 4 | Ovarian cancer: review of the National Institute for Clinical Excellence (NICE) guidance recommendations. <i>Cancer Investigation</i> , 2004 , 22, 730-42 | 2.1 | 22 |
| 3 | Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer. <i>Journal of Clinical Oncology</i> , 2003 , 21, 2492-9 | 2.2 | 173 |
| 2 | Aromatase inhibitors for breast cancer: lessons from the laboratory. <i>Nature Reviews Cancer</i> , 2003 , 3, 821-31 | 31.3 | 220 |
| 1 | BMS-214662 (Bristol-Myers Squibb). <i>IDrugs: the Investigational Drugs Journal</i> , 2003 , 6, 72-8 | | 1 |